Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis

David Dowdy and colleagues discuss the complexities of costing new TB diagnostic tests, including GeneXpert, and argue that flexible analytic tools are needed for decision-makers to adapt large-sample cost-effectiveness data to local conditions.

[1]  Z. Bisoffi,et al.  Why Are Clinicians Reluctant to Treat Smear-Negative Tuberculosis? An Inquiry about Treatment Thresholds in Rwanda , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  J. Kassirer,et al.  The threshold approach to clinical decision making. , 1980, The New England journal of medicine.

[3]  N Waugh,et al.  A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. , 2007, Health technology assessment.

[4]  R. Chaisson,et al.  Impact and Cost-Effectiveness of Culture for Diagnosis of Tuberculosis in HIV-Infected Brazilian Adults , 2008, PloS one.

[5]  M. Perkins,et al.  Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  D. Dowdy,et al.  Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[7]  M. Nicol,et al.  Beyond accuracy: creating a comprehensive evidence base for tuberculosis diagnostic tools , 2010 .

[8]  M. Weinstein,et al.  The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[9]  T. Frieden.  Lessons from tuberculosis control for public health. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[10]  A. Horvath,et al.  Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. , 2009, Clinical chemistry.

[11]  Madhukar Pai,et al.  Commercial Nucleic-Acid Amplification Tests for Diagnosis of Pulmonary Tuberculosis in Respiratory Specimens: Meta-Analysis and Meta-Regression , 2008, PloS one.

[12]  E. Vittinghoff,et al.  Evaluating tuberculosis case detection via real-time monitoring of tuberculosis diagnostic services. , 2011, American journal of respiratory and critical care medicine.

[13]  R. Baltussen,et al.  Cost effectiveness analysis of strategies for tuberculosis control in developing countries , 2005, BMJ : British Medical Journal.

[14]  J. Sachs.  Macroeconomics and health: investing in health for economic development , 2002 .

[15]  M. Nicol,et al.  Beyond accuracy: creating a comprehensive evidence base for TB diagnostic tools. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[16]  P. Klatser,et al.  Cost-effectiveness analysis of PCR for the rapid diagnosis of pulmonary tuberculosis , 2010 .

[17]  R. Chaisson,et al.  Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention , 2007, Clinical trials.

[18]  Weighing Harm in Therapeutic Decisions of Smear-Negative Pulmonary Tuberculosis , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[19]  Karen Steingart,et al.  New and improved tuberculosis diagnostics: evidence, policy, practice, and impact , 2010, Current opinion in pulmonary medicine.

[20]  R. Feachem.  Commission on Macroeconomics and Health. , 2002, Bulletin of the World Health Organization.

[21]  Eduardo Gotuzzo,et al.  Rapid molecular detection of tuberculosis and rifampin resistance. , 2010, The New England journal of medicine.

[22]  Eduardo Gotuzzo,et al.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study , 2011, The Lancet.

[23]  M. Gold,et al.  Panel on cost-effectiveness in health and medicine. , 1996, Medical care.